GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer.

Abstract

A confluence of factors, most prominently the recognition of GI stromal tumor (GIST) as a specific sarcoma subtype and the availability of imatinib, led to the "Big Bang" of GIST therapy (ie, the successful treatment of the first patient with GIST with imatinib in 2000). The trail blazed by imatinib for chronic myelogenous leukemia and GIST has become a… (More)
DOI: 10.1200/JCO.2014.59.7344

Topics

Cite this paper

@article{Cioffi2015GIST, title={GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer.}, author={Angela Cioffi and Robert G. Maki}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2015}, volume={33 16}, pages={1849-54} }